CycleGuard® 500, a melengestrol acetate feed additive used for increased rate of weight gain, improved feed efficiency and suppression of estrus (heat) in heifers, has received U.S. Food & Drug Administration approval for combination use with other drug feed additive products in the manufacture of Type B and C medicated feeds.
Available as a Type A liquid medicated article from Huvepharma®, CycleGuard® 500 must be mixed with other feeds when fed, and should be fed according to label directions. The combination approvals, or Blue Bird labels, allow CycleGuard® 500 to also be used with other feed additives commonly fed to feedlot cattle to enhance rate of gain, feed efficiency, promote carcass leanness, and control coccidiosis, including monensin, tylosin and ractopamine hydrochloride and more.
The CycleGuard® 500 combinations receiving FDA approval include CycleGuard® 500 and Monovet® 90; CycleGuard, with Monovet® 90 and Optigrid® 45; CycleGuard, with Monovet® 90 and Tylovet® 100; CycleGuard with Monovet® 90, Tylovet® 100 and Optigrid® 45, as well as CycleGuard with Optigrid® 45 and Monovet® 90 plus and CycleGuard with Optigrid® 45, Monovet® 90 and Tylovet® 100.
“Huvepharma is focused on offering quality product choices and technical expertise to livestock producers and feeders to aid the industry in enhancing production and efficiency. CycleGuard® 500 used with these combination approvals provides one more tool available toward that effort,” says J. Free, director of U.S. Cattle Business for Huvepharma.
Huvepharma has offered animal health products for poultry, swine and cattle in the U.S. since 2005. In addition to CycleGuard®
500, over the past 18 months the company has received FDA approvals for Monovet® 90, the first available bio-equivalent monensin, and Optigrid®
45, comprised of the active ingredient ractopamine hydrochloride.
In January 2021, Huvepharma also received FDA approval for four Blue Bird label combinations with Optigrid®45, a ractopamine hydrochloride Type A medicated article used increased rate of weight gain, improved feed efficiency and increased carcass leanness in cattle fed in confinement for slaughter.
About Huvepharma
Huvepharma Inc. is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. A privately-owned company headquartered in Sofia, Bulgaria, Huvepharma’s U.S. headquarter are located in Peachtree City, GA.
